Back to Search
Start Over
Intravenous Artesunate for the Treatment of Severe and Complicated Malaria in the United States: Clinical Use Under an Investigational New Drug Protocol
- Source :
- Annals of internal medicine. 163(7)
- Publication Year :
- 2015
-
Abstract
- Quinidine gluconate, the only U.S. Food and Drug Administration-approved treatment for life-threatening malaria in the United States, has a problematic safety profile and is often unavailable in hospitals.To assess the safety and clinical benefit of intravenous artesunate as an alternative to quinidine.Retrospective case series.U.S. hospitals.102 patients aged 1 to 72 years (90% adults; 61% men) with severe and complicated malaria. Patients received 4 weight-based doses of intravenous artesunate (2.4 mg/kg) under a treatment protocol implemented by the Centers for Disease Control and Prevention between January 2007 and December 2010. At baseline, 35% had evidence of cerebral malaria, and 17% had severe hepatic impairment. Eligibility required the presence of microscopically confirmed malaria, need for intravenous treatment, and an impediment to quinidine.Clinical and laboratory data from each patient's hospital records were abstracted retrospectively, including information from baseline through a maximum 7-day follow-up, and presented before a physician committee to evaluate safety and clinical benefit outcomes.7 patients died (mortality rate, 6.9%). The most frequent adverse events were anemia (65%) and elevated hepatic enzyme levels (49%). All deaths and most adverse events were attributed to the severity of malaria. Patients' symptoms generally improved or resolved within 3 days, and the median time to discharge from the intensive care unit was 4 days, even for patients with severe liver disease or cerebral malaria. More than 100 concomitant medications were used, with no documented drug-drug interactions.Potential late-presenting safety issues might occur outside the 7-day follow-up.Artesunate was a safe and clinically beneficial alternative to quinidine.
- Subjects :
- Drug
Adult
Male
medicine.medical_specialty
Pediatrics
Adolescent
media_common.quotation_subject
Artesunate
macromolecular substances
Parasitemia
Article
Medication Adherence
chemistry.chemical_compound
Antimalarials
Young Adult
parasitic diseases
Internal Medicine
medicine
Humans
Intensive care medicine
Adverse effect
Child
media_common
Aged
Retrospective Studies
Quinine
business.industry
Quinidine Gluconate
Investigational New Drug
Infant
General Medicine
Drugs, Investigational
Middle Aged
medicine.disease
Artemisinins
United States
Malaria
Treatment Outcome
chemistry
Cerebral Malaria
Child, Preschool
Injections, Intravenous
Drug Therapy, Combination
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 15393704
- Volume :
- 163
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Annals of internal medicine
- Accession number :
- edsair.doi.dedup.....d855d841bad5d187ede08a367a32f487